NDA/BLA filed

“On December 30, 2025, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that that it has completed the rolling submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration (the "FDA") seeking approval for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for Glycogen Storage Disease Type Ia ("GSDIa").”